Desk›Healthcare› Suven Life Sciences Ltd
Suven Life Sciences Ltd
BSE 530239 · NSE SUVEN · ISIN INE495B01038 · Group B · Active
Healthcare › Healthcare › Healthcare Services › Healthcare Research, Analytics & Technology
₹367.70
-1.12%
BSE close, 28 August 2026
₹10,389.83 cr
28.3 cr shares · Small cap
₹2,907.68 cr
as published
-184.8× · 12.56×
EPS ₹-1.99 · BV ₹29.28
7.12 / -54.86
₹ cr, as filed
16
3 selected · 19%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -6.4% |
|---|---|
| Against 52-week low | +195.7% |
| Day change | -1.12% |
| Size band | Small cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹-1.99 |
|---|---|
| Price / earnings | -184.77× |
| Price / book | 12.56× |
| Book value — derived, price ÷ P/B | ₹29.28 |
| Return on equity | -6.80% |
| Operating margin | -378.24% |
| Net margin | -452.02% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- -6.80%
- ROE as published
- -6.80%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 3.57 | -16.12 | -0.61 | -378.24% | -452.02% |
| Mar-26 · Q | 1.52 | -11.17 | -0.50 | -620.13% | -734.67% |
| FY25-26 | 7.12 | -54.86 | -2.41 | -689.96% | -771.09% |
Quarter on quarter
- Revenue, quarter on quarter
- +134.9%
- Net profit, quarter on quarter
- -44.3%
- Operating margin, quarter on quarter
- +24,189 bps
Disclosure profile 16 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Press Release | 1 |
| Results | 1 |
| Selected sub-total | 3 |
| Procedural | |
| AGM / EGM | 3 |
| Newspaper Publication | 2 |
| Annual Report | 1 |
| BRSR | 1 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| General | 1 |
| Monitoring Agency | 1 |
| SAST | 1 |
| Trading Window | 1 |
| Procedural sub-total | 13 |
| Total | 16 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
16 filings · 3 selected · busiest 2026-07-30
Filing rhythm · the twelve most recent
2026-07-302026-10-07
SelectedProcedural
Filings
16 in the window · 16 earlier on record
-
7 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
28 September 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
3 September 2026 ·
Press Release / Media Release
Please find enclosed the News release
Company Update / Press Release / Media Release View filing →
-
25 August 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Report of Scrutinizer
AGM/EGM / AGM View filing →
-
25 August 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of 37th Annual General Meeting
AGM/EGM / AGM View filing →
-
11 August 2026 ·
Monitoring Agency Report
Monitoring Agency Report for the quarter ended 30th June, 2026
Company Update / Monitoring Agency Report View filing →
-
7 August 2026 ·
Newspaper Publication
Newspaper publication- un-audited finacial results
Company Update / Newspaper Publication View filing →
-
6 August 2026 ·
Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended June 30, 2026
Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026
Board Meeting / Outcome of Board Meeting View filing →
-
6 August 2026 ·
Un-Audited Financial Results For The Quarter Ended 30Th June, 2026
Un-audited Financial results for the quarter ended 30th June, 2026
Result / Financial Results View filing →
-
31 July 2026 ·
Newspaper Publication
Newspaper Adv. regarding Notice of 37th Annual General Meeting of the Company and E-voting information
Company Update / Newspaper Publication View filing →
-
30 July 2026 ·
Board Meeting Intimation for Consideration Of Un-Audited Financial Results (Standalone And Consolidated) For The Quarter Ended 30Th June, 2026
Suven Life Sciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Un-Audited Financial Results ....
Board Meeting / Board Meeting View filing →
-
30 July 2026 ·
Letter To Shareholders Regarding Annual Report FY 2025-26
Letter to Shareholders regarding Annual Report FY 2025-26
Company Update / General View filing →
-
30 July 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report (BRSR) for FY 2025-26
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
30 July 2026 ·
Notice Of 37Th Annual General Meeting (AGM) Of The Company
Notice of the 37th Annual General Meeting (AGM) of the Company
AGM/EGM / AGM View filing →
-
30 July 2026 ·
Reg. 34 (1) Annual Report.
Annual Report 2025-26 and Notice of 37th Annual General Meeting (AGM) of the Company
Others / Reg. 34 (1) Annual Report View filing →
-
20 July 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & PACs
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
RSS feed for Suven Life Sciences Ltd · the 50 most recent filings